Trade

Watchlist

Portfolio

Message

Set Alert

BSE LIVE NSE LIVE 26 Aug, 2025 12:21 Volume Todays L/H More ×

Sun Pharmaceutical Industries Ltd. reported a 2.6% year-on-year rise in net profit to Rs 3,118 crore for the quarter ended September 30, 2025, as strong growth in its innovative medicines portfolio offset weakness in the US generics business.

The net profit rose to Rs 3,118 crore in Q2FY26 from ₹3037.3 crore a year earlier. Revenue climbed 8.6% to Rs 14,405.2 crore, driven by double-digit growth in India, emerging markets, and rest of world (RoW) geographies.

EBITDA grew 14.9% to Rs 4,527.1 crore, with margins expanding to 31.3%. R&D spend stood at Rs 7,827 million, or 5.4% of sales.

"India, Emerging Markets and Rest of World led our growth for the period

See Full Page